Eupraxia Pharmaceuticals Inc

NEW
NAS:EPRX (Canada)   Ordinary Shares
$ 6.59 +0.19 (+2.96%) 10:08 PM EST
At Loss
P/B:
3.91
Market Cap:
$ 431.47M
Enterprise V:
$ 322.76M
Volume:
794.01K
Avg Vol (2M):
326.72K
Trade In:
Volume:
794.01K
At Loss
Avg Vol (2M):
326.72K

Business Description

Eupraxia Pharmaceuticals Inc
NAICS : 541710 SIC : 3741
ISIN : CA29842P1053

Share Class Description:

EPRX: Ordinary Shares

Total Employee Number:

49
Description
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.
Name Current Vs Industry Vs History
Cash-To-Debt
69.19
Equity-to-Asset
0.95
Debt-to-Equity
0.02
Debt-to-EBITDA
-0.04
Interest Coverage
N/A
N/A
N/A
Piotroski F-Score
2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI
64.47
9-Day RSI
56.19
14-Day RSI
51.51
3-1 Month Momentum %
9.93
6-1 Month Momentum %
-0.26
12-1 Month Momentum %
62.99

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio
19.3
Quick Ratio
19.3
Cash Ratio
18.86

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio
-34
Shareholder Yield %
-12.99
Name Current Vs Industry Vs History
ROE %
-61.33
ROA %
-58.78
ROIC %
-3135.89
3-Year ROIIC %
74582.05
ROC (Joel Greenblatt) %
-3616.52
ROCE %
-67
Moat Score
3
Tariff Resilience Score
5

GF Value™

Eupraxia Pharmaceuticals Inc Filings

Filing Date Document Date Form
No Filing Data

Eupraxia Pharmaceuticals Inc Stock Events

Financials Calendars
Event Date Price ($)
Third quarter earnings results for 2026 2026-11-04 In 128 days
Second quarter earnings results for 2026 2026-08-12 In 44 days
General meeting for 2025 2026-06-18 10:00 6.29 (+4.66%)
Jefferies Global Healthcare Conference 2026-06-03 17:30 6.65 (-3.62%)
First quarter earnings results for 2026 2026-05-12 7.42 (+0.41%)
Guidance call for 2026 2026-04-21 11:00 7.20 (+2.27%)
Annual report for 2025 2026-03-12 7.69 (-3.51%)
Fourth quarter earnings results for 2025 2026-03-12 7.69 (-3.51%)
Third quarter earnings results for 2025 2025-11-04 6.09 (+7.79%)
Second quarter earnings results for 2025 2025-08-12 5.33 (+1.24%)
Show
Entries

Guru Commentaries on NAS:EPRX

No articles.

Articles on Eupraxia Pharmaceuticals Inc

No articles.

Headlines

See More
  • 1
No news.
  • 1